Ignite Creation Date:
2025-12-24 @ 7:47 PM
Ignite Modification Date:
2026-01-02 @ 1:05 AM
Study NCT ID:
NCT06048003
Status:
RECRUITING
Last Update Posted:
2023-12-26
First Post:
2023-09-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Armenian National Registry of Myocardial Infarction
Sponsor:
Armenian Cardiologists Association
Organization:
Study Overview
Official Title:
Armenian National Registry of ST-elevation Myocardial Infarction,a Multicenter Prospective Observational Study With Biocollection
Status:
RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ARMI
Brief Summary:
This is a national, multicenter prospective observational study of patients presenting to hospitals in Armenia with STEMI diagnosis.
The main questions it aims to answer are:
* Determine the rate of in-hospital mortality for the patients with STEMI admitted to the participating hospitals.
* Compare short and long-term CV and all-cause mortality and hospitalization.
* Determine how professional guidelines are followed in real-world situations.
The main questions it aims to answer are:
* Determine the rate of in-hospital mortality for the patients with STEMI admitted to the participating hospitals.
* Compare short and long-term CV and all-cause mortality and hospitalization.
* Determine how professional guidelines are followed in real-world situations.
Detailed Description:
Although the state program on primary percutaneous coronary intervention in ST elevated myocardial infarction, which was launched in 2015 helped to drastically decrease STEMI mortality rates, patients who had survived usually develop heart failure (HF) which leads to increased economic burden for the Armenian healthcare system.
The total duration of the study will be 24 months. The target number of the inclusion is 2500 patients. The follow-up period for enrolled patients will be 12 months.
The total duration of the study will be 24 months. The target number of the inclusion is 2500 patients. The follow-up period for enrolled patients will be 12 months.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: